Jiang Shan, Wang Yujing, Ren Younan, Tang Qinglian, Xue Chu, Wang Zhi, Zhang Qi, Hu Yixin, Wang Hongbo, Zhao Fang, Zhu Michael X, Cao Zhengyu
State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Department of Gastroenterology, Zhongda Hospital, Nanjing, China.
Br J Pharmacol. 2025 Oct;182(20):5004-5022. doi: 10.1111/bph.17431. Epub 2025 Jan 29.
Genetic ablation or inhibition of the cation channel TRPC6 is protective against renal, cardiac and intestinal fibrosis. However, TRPC6 expression is decreased in patients with liver diseases. Here, we explored the role of TRPC6 in liver fibrosis and the underlying mechanism.
Bile duct ligation and thioacetamide gavage were used to model liver fibrosis in C57BL/6J mice. Western blotting, immunolabelling and qPCR were employed for protein and mRNA expression. Liver injury/fibrosis were assessed using serum alanine transaminase and aspartate transaminase assays, haematoxylin-eosin, Masson and Sirius red staining. Adenoviruses were used to overexpress TRPC6 and CREB1. ChIP and dual-luciferase reporter assays were performed to test the direct inhibition of Acta2 transcription by CREB.
TRPC6 protein levels were decreased in fibrotic liver tissues from both patients and mice, with the decrease being more robust in fibrotic areas. In hepatic stellate cells (HSCs), TRPC6 ablation aggravated liver injury and fibrosis, which was alleviated by overexpressing TRPC6. In primary cultured HSCs, deletion of TRPC6 exacerbated self-activation of HSCs, which was reversed by restoration of TRPC6 expression. Mechanistically, TRPC6 suppressed HSC activation through CaMK4-mediated CREB phosphorylation. CREB directly interacted with the promoter region of Acta2 to inhibit its transcription. Expression of a constitutively active form of CREB1 (CREB1) in HSCs attenuated BDL-induced liver injury/fibrosis in TRPC6 knockout mice.
Deficiency of TRPC6 aggravates liver injury/fibrosis through augmentation of HSC activation. Increasing TRPC6 expression/function would be therapeutically beneficial for fibrotic liver diseases.
This article is part of a themed issue Drugs and Drug Targets in Metabolic and Chronic Inflammatory Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.20/issuetoc.
阳离子通道TRPC6的基因消融或抑制可预防肾、心脏和肠道纤维化。然而,在肝病患者中TRPC6表达降低。在此,我们探究了TRPC6在肝纤维化中的作用及其潜在机制。
采用胆管结扎和硫代乙酰胺灌胃法建立C57BL/6J小鼠肝纤维化模型。运用蛋白质印迹法、免疫标记法和定量聚合酶链反应检测蛋白质和mRNA表达。通过血清丙氨酸转氨酶和天冬氨酸转氨酶测定、苏木精-伊红染色、Masson染色和天狼星红染色评估肝损伤/纤维化。使用腺病毒过表达TRPC6和CREB1。进行染色质免疫沉淀和双荧光素酶报告基因检测以测试CREB对Acta2转录的直接抑制作用。
患者和小鼠的纤维化肝组织中TRPC6蛋白水平均降低,在纤维化区域降低更为显著。在肝星状细胞(HSC)中,TRPC6缺失加重肝损伤和纤维化,而过表达TRPC6可缓解此情况。在原代培养的HSC中,TRPC6缺失加剧了HSC的自我激活,恢复TRPC6表达可使其逆转。机制上,TRPC6通过CaMK4介导的CREB磷酸化抑制HSC激活。CREB直接与Acta2的启动子区域相互作用以抑制其转录。在HSC中表达组成型活性形式的CREB1(CREB1)可减轻TRPC6基因敲除小鼠中胆管结扎诱导的肝损伤/纤维化。
TRPC6缺乏通过增强HSC激活加重肝损伤/纤维化。增加TRPC6表达/功能对纤维化肝病具有治疗益处。
本文是主题为“代谢和慢性炎症性疾病中的药物与药物靶点”的特刊的一部分。若要查看本节中的其他文章,请访问http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.20/issuetoc。